Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2006 3
2007 1
2008 3
2009 3
2010 5
2011 4
2012 12
2013 9
2014 14
2015 11
2016 11
2017 13
2018 13
2019 14
2020 11
2021 11
2022 8
2023 10
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
The role of RNA modifications in disease-associated macrophages.
Huart C, Gupta MS, Van Ginderachter JA. Huart C, et al. Mol Ther Nucleic Acids. 2024 Aug 26;35(4):102315. doi: 10.1016/j.omtn.2024.102315. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39296330 Free PMC article. Review.
Infection history imprints prolonged changes to the epigenome, transcriptome and function of Kupffer cells.
Musrati MA, Stijlemans B, Azouz A, Kancheva D, Mesbahi S, Hadadi E, Lebegge E, Ali L, De Vlaminck K, Scheyltjens I, Vandamme N, Zivalj M, Assaf N, Elkrim Y, Ahmidi I, Huart C, Lamkanfi M, Guilliams M, De Baetselier P, Goriely S, Movahedi K, Van Ginderachter JA. Musrati MA, et al. J Hepatol. 2024 Dec;81(6):1023-1039. doi: 10.1016/j.jhep.2024.07.007. Epub 2024 Jul 11. J Hepatol. 2024. PMID: 39002639 Free article.
Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatids.
Stijlemans B, De Baetselier P, Van Molle I, Lecordier L, Hendrickx E, Romão E, Vincke C, Baetens W, Schoonooghe S, Hassanzadeh-Ghassabeh G, Korf H, Wallays M, Pinto Torres JE, Perez-Morga D, Brys L, Campetella O, Leguizamón MS, Claes M, Hendrickx S, Mabille D, Caljon G, Remaut H, Roelants K, Magez S, Van Ginderachter JA, De Trez C. Stijlemans B, et al. Nat Commun. 2024 Feb 27;15(1):1779. doi: 10.1038/s41467-024-46067-4. Nat Commun. 2024. PMID: 38413606 Free PMC article.
Current status and future expectations of nanobodies in oncology trials.
De Pauw T, De Mey L, Debacker JM, Raes G, Van Ginderachter JA, De Groof TWM, Devoogdt N. De Pauw T, et al. Expert Opin Investig Drugs. 2023 Jul-Dec;32(8):705-721. doi: 10.1080/13543784.2023.2249814. Epub 2023 Aug 28. Expert Opin Investig Drugs. 2023. PMID: 37638538 Review.
Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).
Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, Breckpot K, Lecocq Q, Decoster L, Fontaine C, Schallier D, Aspeslagh S, Vaneycken I, Raes G, Van Ginderachter JA, Lahoutte T, Caveliers V, Keyaerts M. Gondry O, et al. J Nucl Med. 2023 Sep;64(9):1378-1384. doi: 10.2967/jnumed.122.264853. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474271 Free PMC article. Clinical Trial.
147 results